Purpura, Thrombotic Thrombocytopenic: all 64 studies

Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.

• Daratumumab in Immune-mediated Thrombotic Thrombocytopenic PurpuraRecruitingNCT07513948
• A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access ProgramRecruitingNCT07429942
• A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With AdzynmaRecruitingNCT07353099
• Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA CenterRecruitingNCT07205861
• Immunological Aspect of Thrombotic Thrombocytopenic Purpura (TTP)RecruitingNCT06945861
• BCMA-CD19 CAR-T Therapy for Refractory Autoimmune DiseasesRecruitingNCT06794008Phase 2
• Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669
• A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraRecruitingNCT06441578
• Italian iTTP RegistryRecruitingNCT06376786
• Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter StudyRecruitingNCT05950750
• Spanish-Portuguese Thrombotic Thrombocytopenic Purpura RegistryRecruitingNCT05914441
• Construction of a Database for TTPRecruitingNCT05571774
• Aspirin for Prophylaxis of TTPNot yet recruitingNCT05568147Phase 2/3
• .German TTP-Registry (Thrombotic Thrombocytopenic Purpura)RecruitingNCT05389007
• Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTPNot yet recruitingNCT05135442Phase 4
• A Prospective Study on the Long-Term Vascular Burden in Thrombotic Thrombocytopenic Purpura PatientsRecruitingNCT03187652
• Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)RecruitingNCT01257269
• Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic PurpuraCompletedNCT05468320Phase 3Results posted
• Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)CompletedNCT03922308Phase 2Results posted
• A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)CompletedNCT03393975Phase 3Results posted
• Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)CompletedNCT02878603Phase 3Results posted
• IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) PatientsTerminatedNCT02854059Phase 2Results posted
• Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic PurpuraCompletedNCT02553317Phase 3Results posted
• Low Dose Rituximab in Thrombotic Thrombocytopenic PurpuraCompletedNCT01554514Phase 2Results posted
• Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)CompletedNCT01151423Phase 2Results posted
• Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)TerminatedNCT00953771Phase 2Results posted
• Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)TerminatedNCT00799773Phase 3Results posted
• Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)CompletedNCT00713193Phase 3Results posted
• MICROVASCULAR DAMAGE IN THROMBOTIC THROMBOCYTOPENIC PURPURAActive, not recruitingNCT07615244Not applicable
• Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic PurpuraCompletedNCT05876221
• A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)Status unknownNCT05785468
• Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)Approved for marketingNCT05770219
• A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)CompletedNCT05714969Phase 2
• SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk PopulationsWithdrawnNCT05393999Phase 2
• A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)Status unknownNCT05262881
• Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic PurpuraActive, not recruitingNCT05046717
• Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTPActive, not recruitingNCT04985318
• The ConNeCT Study: Neurological Complications of TTPStatus unknownNCT04981028
• A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraActive, not recruitingNCT04683003Phase 3
• Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune ThrombocytopeniaStatus unknownNCT04588194Phase 2
• A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)CompletedNCT04074187Phase 2/3
• A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)Status unknownNCT04021173Phase 2
• The United Kingdom Thrombotic Thrombocytopenic Purpura Registry (UK TTP Registry)Status unknownNCT03832881
• TTP and aHUS in Complicated PregnanciesStatus unknownNCT03605511
• Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]CompletedNCT03519672
• Observational Study of the Use of octaplasLG®.CompletedNCT03369314
• Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive CareStatus unknownNCT03237819Phase 3
• The Role of Microparticles as a BiomarkerWithdrawnNCT02626663
• Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)CompletedNCT02216084Phase 1
• Early Predictive Factors of Cardiac and Cerebral Involvement in TMACompletedNCT02134171Not applicable
• Octaplas Adult TTP TrialTerminatedNCT01938404
• At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic ConditionsCompletedNCT01931644
• A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia PurpuraCompletedNCT01808521Early Phase 1
• Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic PurpuraWithdrawnNCT01754545Phase 4
• The Plasma Large-Volume Exchange RCTWithdrawnNCT01433003Phase 3
• The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)CompletedNCT00937131Phase 2
• Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic PurpuraCompletedNCT00907751Phase 2
• Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic MicroangiopathyTerminatedNCT00726544Phase 2
• ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function DisordersCompletedNCT00632242Phase 2
• International Registry and Biorepository for TMA(Thrombotic Microangiopathy)TerminatedNCT00593229
• Rituximab in Patients With Relapsed or Refractory TTP-HUSStatus unknownNCT00531089Phase 2
• ADAMTS13 in Thrombotic Thrombocytopenic PurpuraCompletedNCT00426686
• Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)TerminatedNCT00411801Phase 3
• Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic PurpuraWithdrawnNCT00251277Phase 1/2

← Purpura, Thrombotic Thrombocytopenic overview